{"entity":{"id":"t-knife","kind":"company","name":"T-Knife","aka":["T-knife","T-knife Therapeutics","T-knife GmbH","T-knife Therapeutics, Inc."],"tldr":"A Berlin company that engineers patients' T cells with receptors that recognise cancer, aiming at solid tumours. Its lead therapy targets PRAME, a marker found in many cancers, and its first trial is planned for 2026.","summary":"T-Knife develops engineered T-cell therapies for solid tumours. Its lead candidate is a TCR-T therapy targeting PRAME, which the company says is found in cancers of the skin, uterus, ovaries, lungs, breasts, oesophagus, kidneys, cervix and head and neck; the T cells carry the company's added enhancements meant to improve fitness and persistence in the tumour. The company says a Phase 1 trial is planned to begin in 2026 after CTA approval, and it lists in vivo programmes as well. T-Knife was founded on technology from the Max Delbruck Center for Molecular Medicine and Charite, with co-founders Thomas Blankenstein and Elisa Kieback. An earlier Phase 1/2 trial of MAGE-A1-directed TCR-T cells in advanced solid tumours (NCT05430555, sponsor T-knife GmbH) is registered as terminated.","asOf":"2026-11-04","links":[{"label":"Official website","url":"https://www.t-knife.com/"},{"label":"Pipeline page","url":"https://www.t-knife.com/pipeline/"},{"label":"About page","url":"https://www.t-knife.com/about/"},{"label":"Imprint (T-knife GmbH, Berlin)","url":"https://www.t-knife.com/imprint/"},{"label":"ClinicalTrials.gov NCT05430555","url":"https://clinicaltrials.gov/study/NCT05430555"},{"label":"Andera Partners life sciences page","url":"https://www.anderapartners.com/en/expertise/life-sciences-biotechnologies/"},{"label":"RA Capital portfolio entry","url":"https://www.racap.com/portfolio/t-knife"}],"tags":[],"related":[],"cancers":[],"sections":["cell-therapy","immunotherapy"],"technologies":["tcr-t"],"targets":["prame"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Founding year not stated on the pages read.","Andera Partners is added because its life sciences page carries a T-Knife testimonial among its portfolio companies; check whether that is enough.","No product record: the PRAME TCR-T candidate is preclinical and NCT05430555 does not name a product code.","Cancer ids left empty because no trial of the PRAME TCR-T candidate is registered."],"hq":"Berlin","country":"DE","companyType":"cell-therapy","website":"https://www.t-knife.com/","stage":"startup","investors":["ra-capital","andera-partners"],"funding":[]},"route":"/companies/t-knife/","neighbours":{"section":[{"id":"cell-therapy","kind":"section","name":"Cell Therapy","route":"/fronts/cell-therapy/"},{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"technology":[{"id":"tcr-t","kind":"technology","name":"TCR-T cell therapy","route":"/technologies/tcr-t/"}],"target":[{"id":"prame","kind":"target","name":"PRAME","route":"/targets/prame/"}],"company":[{"id":"andera-partners","kind":"company","name":"Andera Partners","route":"/companies/andera-partners/"},{"id":"ra-capital","kind":"company","name":"RA Capital Management","route":"/companies/ra-capital/"}]}}